Blockbuster Drugs-2015

Future Blockbuster Drugs list by Forecast Analysis

Nivolumab (Opdivo) is a FDA approved drug for advanced metastatic melanoma via a PD-1 immune checkpoint inhibiton. This PD-1 blockers boost the immune system to attack different types of cancerious cells. Actually BMS' nivolumab is under study to kill other cancer types, including lung, kidney, brain, and lymphoma. FDA approved recently, so peak sales could reach around $6 billion by 2019.

Praluent (alirocumab) is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) in development for the treatment of patients with high cholesterol discovered by Regeneron Pharmaceuticals and co-developed with Sanofi. The market analyst expect that it is a one of the blockbuster drug in 2015 and forecast sales may reach $4.41 billion by 2019.

Novartis LCZ696 (valsartan/sacubitril) is an Angiotensin Receptor Neprilysin Inhibitor (ARNI) with a novel mechanism of action that ultimately reduces strain on the failing heart. In the PARADIGM-HF study, LCZ696 was superior to ACE inhibitor enalapril and reduced the risk of death from cardiovascular causes and heart failure by around 21%. Analysts predict that it is a one of the block buster drug in 2015 could peak at $3.73 billion by 2019.

One of the top leading pharmaceutical MNC Pfizer is looking toward to a next new year in R&D with FDA approved palbociclib (Ibrance) in February 2015, which is marketed as a future mega-blockbuster drug. Palbociclib is a CDK4/6 inhibitor for breast cancer combination with letrozole. Moreover it is also received breakthrough drug status. Pfizer received FDA approval in treatment-naive, postmenopausal women with metastatic ER+, HER2-breast cancer. Although forecast Analysis says that sales raises at roughly $2.75 billion a year by 2019.

The combination of lumacaftor and ivacaftor is the first potential medicine, which is designed to treat cystic fibrosis in people with two copies of the F508del mutation. This comibination is a Breakthrough Therapy Designation in late 2012.Ivacaftor (Kalydeco) was already FDA-approved in 2012 for patients with just one mutation copy. Vertex is seeking approval to initiate expanded access for critical patients in Q1 or Q2 of 2015. Analyst forecast prediction indicates that annual sales of the drug combination may reach $2.73 billion by 2019.

Viekira Pak is a multipill, antiviral containing a combination of dasabuvir, ombitasvir, paritaprevir, and ritonavir. These four drugs are antiviral medicines that prevent hepatitis C virus (HCV) cells from multiplying in body discovered by Abbvie Inc. Viekira Pak is used to treat genotype 1 chronic hepatitis C in adults, including people with a certain type of cirrhosis. The market analyst expect that it is a one of the blockbuster drug in 2015 and forecast sales may reach $2.5 billion by 2019.

Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia discovered and developed by Amgen and Astellas. Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).The market analyst expect that it is a one of the blockbuster drug in 2015 and forecast sales may reach $1.86 billion by 2019.

Gardasil 9 FDA approved Merck new vaccine offers protection against five more types of HPV than the older Gardasil vaccine, and has the potential to help prevent 90% of cervical cancers caused by HPV. The market analyst expect that it is a one of the blockbuster drug in 2015 and forecast sales may reach $1.63 billion by 2019.

Brexpiprazole is a novel D2 dopamine partial agonist for monotherapy in adult patients with schizophrenia and for adjunctive treatment of major depressive disorder (MDD) in adult patients discovered and developed by Otsuka and Lundbeck. The market analyst expect that it is a one of the blockbuster drug in 2015 and forecast sales may reach $1.35 billion by 2019.

Toujeo is a once-daily, long-acting basal insulin (glargine) used to treat adults with type 2 and type 1 diabetes for the control of high blood sugar. It is a Sanofi’s blockbuster Lantus, but a stronger version. In Toujeo, each milliliter of liquid carries 300 units of insulin, whereas Lantus only carries 100 units of insulin per milliliter. The market analyst expect that it is a one of the blockbuster drug in 2015 and forecast sales may reach $1.26 billion by 2019.

Secukinumab (Cosentyx) is a FDA approved for the treatment of moderate-to-severe plaque psoriasis. It is a selective interleukin-17A (IL-17A) inhibitor and administered via injection under the skin. Cosentyx’s safety and effectiveness were demonstrated against a total of 2,403 candidates with plaque psoriasis who were candidates for phototherapy or systemic therapy. Cosentyx is a first-in-class monoclonal antibody (mAb) for plaque psoriasis with expected sales around $1.08 billion by 2019.

Table: List of Blockbuster Drugs-2015

Pharma company	Drug Name	Disease	Structure	2019 Predicted forecast sales in billion $
Bristol-myers and Ono	Nivolumab (Opdivo)	Metastatic melanoma	monoclonal antibody	$ 5.68
Regeneron and Sanofi	Praluent (alirocumab)	Hypercholesterolemia	monoclonal antibody	$ 4.41
Novartis	LCZ-696 (Valsartan/sacubitril)	Chronic heart failure		$ 3.73
Pfizer	Palbociclib (Ibrance)	Breast cancer		$ 2.75
Vertex	Lumacaftor and Ivacaftor	Cystic fibrosis		$ 2.73
Abbvie	Viekira Pak	Hepatitis C		$ 2.5
Amgen and Astellas	evolocumab	Hypercholesterolemia/Hyperlipidemia	monoclonal antibody	$ 1.86
Merck and Co	Gardasil 9	human papillomavirus (HPV)	Vaccine	$ 1.63
Otsuka and Lundbeck	Brexpiprazole	Depression and Schizophrenia		$ 1.35
Sanofi	Toujeo	diabetes	basal insulin analogue	$ 1.26
Novartis	Cosentyx	Psoriasis and Psoriatic arthritis	monoclonal antibody	$ 1.08

You can get more information regarding Blockbuster drugs-2015 from below given PDFs link

• 2015-Drugs to watch Download